Related Experiment Video

Updated: Jul 7, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

[New drugs; sunitinib and sorafenib]

H van Bronswijk1, E A Dubois, S Osanto

  • 1Leids Universitair Medisch Centrum, Albinusdreef 2, 2333 ZA, Leiden.

Nederlands Tijdschrift Voor Geneeskunde
|February 9, 2008
PubMed

Insights

Sunitinib and sorafenib treat advanced kidney cancer by inhibiting tumor growth and angiogenesis. They differ in side effects, with sunitinib causing fatigue and sorafenib causing diarrhea, rash, and hypertension.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Advanced kidney carcinoma, particularly clear cell type, presents treatment challenges after initial therapies fail.
  • Sunitinib and sorafenib are targeted therapies used in advanced renal cell carcinoma (RCC).

Purpose of the Study:

  • To compare the mechanisms of action and adverse effect profiles of sunitinib and sorafenib in treating advanced kidney carcinoma.
  • To provide an overview of these targeted therapies for clinicians and researchers.

Main Methods:

  • Review of pharmacological mechanisms of sunitinib and sorafenib.
  • Analysis of reported clinical data on efficacy and adverse events for both drugs.

Main Results:

  • Both sunitinib and sorafenib inhibit tyrosine-kinase activity of growth factor receptors, impacting tumor cell growth and angiogenesis.
  • Sorafenib additionally inhibits serine/threonine-kinase activity.
  • Sunitinib's common side effects include fatigue and gastrointestinal issues.
  • Sorafenib's frequent adverse effects include diarrhea, rash, palmar-plantar erythrodysaesthesia syndrome, and hypertension.

Conclusions:

  • Sunitinib and sorafenib represent important therapeutic options for advanced clear cell kidney carcinoma.
  • Understanding their distinct mechanisms and side effect profiles is crucial for patient management and treatment selection.

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...